Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
OT:
SCAM YOUR AZZ DoubleDik:
MIAMI, FLORIDA, Oct. 25 -/E-Wire/-- The Export Import Bank of the United States has approved Comprehensive Guarantee to cover U.S. Loan of $9.38million to fund establishment of Xechem Pharmaceutical Plant in Abuja, Nigeria, estimated to cost $12.45million. UPS Capital Business Credit of Hartford, Connecticut is the U.S. Lender providing related Loan for the Project, while Access Bank, Plc. and Diamond Bank, Plc., are to provide Nigerian Bank Guarantees in support of the Project Loan. The Xechem Pharmaceutical Project Loan has been successfully packaged by Financialbridge and will be utilized to purchase U.S. manufactured Plants and Machinery to be supplied by leading Pharmaceutical Equipment Vendors and EPC Contractors including Fisher Scientific, APT and NITRA Corp, etc.
The Xechem Pharmaceutical Plant in Nigeria will manufacture and commercialize NICOSAN™, a phyto-pharmaceutical used for the treatment of Sickle Cell Disease (SCD), a genetic blood disorder caused by the abnormality in the hemoglobin molecule, affecting approximately 4 million Nigerians and another 6 to 8 million sufferers in the rest of Africa and 16 million worldwide. While the only known cure for SCD is Bone Marrow Transplant, which replaces defective red blood cells with donor healthy cells, NICOSAN™ taken once daily is the first drug to offer patients safe and effective treatment for the prophylactic management of SCD. The U.S. Department of Health and Human Services, Office of Orphan Products Development - Food and Drug Administration (FDA), granted the company Orphan Drug designation for NICOSAN™. The Nigerian National Agency for Food and Drug Administration and Control (NAFDAC) has also approved NICOSAN™ for commercialization.
The Xechem Pharmaceutical Plant will also produce other products for the treatment of Malaria, HIV/AIDS and related complications.
NICOSAN™ was formally launched in Abuja on July 6, 2006 by President Olusegun Obasanjo of Nigeria. In his remarks made at the launching ceremony, President Obasanjo commended Xechem and its chairman, Dr. Ramesh Pandey, for their success in researching and developing this important drug to market and for validating the Government of Nigeria's efforts to commercialize locally developed technologies. Dr. Pandey headed the Research Team, Scientific Advisory Board, Sickle Cell Research, Efficacy and Awareness Advisory Board, composed of Scientists, Doctors, Pharmacologists, etc., that researched, clinically tested and developed NICOSAN™.
Here is one thing about this company that is in the plans. Once a patient is on this medicine, he or she needs to be on it for the rest of their life. XKEM is making sure this product is here for a very long time, for a lot of people, and can handle the capacity of supply and demand.
Give me another penny stock with this criteria. This will not be a penny stock very long, XKEM IS DOING EVERYTHING RIGHT, and other idiots are still calling this a scam company on other boards.
Still accumulating here.
Insider Transaction History Date Name-Position Transaction Shares Price Range Shares Held Mkt Value
September 22, 2006 Chassman Margie Planned Sale 14,131,100 ----- -- $438,064
Longview Fund L P Planned Sale 6,872,270 ----- -- $206,168
September 1, 2006 Chassman Margie Planned Sale 43,195,600 ----- -- $1,252,670
August 14, 2006 New Millennium Biotech Planned Sale 13,577,200 ----- -- $382,877
July 28, 2006 Chassman Margie Planned Sale 44,285,000 ----- -- $1,328,550
July 12, 2006 Alpha Capital Ag Planned Sale 10,934,700 ----- -- $360,845
Alpha Capital Planned Sale 12,850,000 -----
This molecule, 5-HMF, is the most promising molecule to treat sickle cell anemia to come from our research group in more than 30 years," Abraham said.
agreed
Sorry guys, just want to spread the wealth with a better company.
Yup. this scam up 31% today:
XKEM -- Xechem International, Inc.
COMPANY NEWS AND PRESS RELEASES FROM OTHER SOURCES:
U.S. Ex-Im Bank has Approved Comprehensive Guarantee to Support $9.38 Million Loan from UPS Capital to Xechem Pharmaceuticals Nigeria
Oct 18 2006 12:46PM ET
www.MarketGainer.com: Market Gainer Administers Coverage on Xechem International Inc.
Oct 18 2006 11:07AM ET
Stockwire.com: Speak with other shareholders about: (OTCBB: WGLE), (OTCBB: MGNE), (OTCBB: XKEM), (OTCBB: PHEI)
Oct 13 2006 9:42AM ET
Stock Market Alerts LLC: Investment Alerts: HYPF! October 13, 2006
Oct 13 2006 4:07AM ET
Xechem International Inc receives grant for studies on 5-HMF compound
Oct 5 2006 8:56AM ET
Stockguru.com: While Signature Leisure Subsidiary Launches Website, Other Companies Announce Financial Reports, Schedule Programming, Receive Grant, and Form Holding Group
Oct 5 2006 8:39AM ET
HotStockReport.com: XKEM, MODC, MTNA HotStockReport.com Daily Stock Alert
Oct 4 2006 12:49PM ET
Hot Stocks to Watch for Wednesday, October 04, 2006: Best Potential Anti-Sickling Agent in 30 Years!
Oct 4 2006 9:13AM ET
TheSUBWAY.com Posts Stock Pick List: Receiving Grant for Further Drug Studies!
Oct 4 2006 9:07AM ET
Xechem Receives $473,181 SBIR Grant From NIH-NHLBI to Conduct Toxicity Studies of 5-HMF Compound
Oct 4 2006 6:30AM ET
Best scam I ever made $$ in.
All the way to the bank rookie!!
The company is based out of New Jersy and last run was till .11, how many penny stock companies get 9 mil in loans and 500K in grants, you punk azz rookie.
How many penny stocks get 9 mil loans , 500K grants and a 3 mil loan, BOOOOOOOOOOOOYA
U.S. Ex-Im Bank has Approved Comprehensive Guarantee to Support $9.38 Million Loan from UPS Capital to Xechem Pharmaceuticals Nigeria
October 18, 2006 12:46:09 (ET)
NEW BRUNSWICK, N.J., Oct 18, 2006 (BUSINESS WIRE) -- Xechem International, Inc. (XKEM, Trade) announced today that the United States Export Import (Ex-Im) Bank, the official credit export agency of the United States, has approved a Comprehensive Credit Guarantee to support a $9.38 million loan from UPS Capital Business Credit to Xechem Pharmaceuticals Nigeria, Ltd. (Xechem Nigeria). Two Nigerian banks, Access Bank Plc. and Diamond Bank, Plc., are to provide the required Nigerian local bank guarantees in favor of Ex-Im Bank.
Funds Earmarked for Establishment of State-of-the-Art Pharmaceutical Facility in Sheda Science Village, Sheda, FCT, Abuja, Nigeria
The funds to be provided by UPS Capital under the Ex-Im guaranteed loan will be used to purchase the U.S. manufactured plant equipment and machinery needed by Xechem Nigeria to establish a state-of-the-art pharmaceutical facility. The first phase of construction of the new facility began in July of this year. The total cost of the project is estimated at $12.45 million, of which $9.38 million will come from the U.S. loan. The expanded pharmaceutical facility, once completed, will enable Xechem Nigeria to produce commercial scale quantities of NICOSAN(TM), Xechem's breakthrough medicine for the prophylactic management of Sickle Cell Disease (SCD).
Xechem Nigeria received regulatory approval for the manufacture, sales and marketing of NICOSAN(TM) from Nigeria's National Agency for Food and Drug Administration and Control (NAFDAC) on July 3rd, 2006, and officially launched the drug just a few days later at a ceremony presided over by His Excellency, General Olusegun Obasanjo, the President of Nigeria. The drug is currently being produced by Xechem Nigeria in limited quantities at its pilot-scale facility in Abuja.
Dr. Ramesh Pandey, Chairman and CEO of the Xechem Companies said, "We are very pleased that this most anticipated guarantee from the U.S. Ex-Im Bank has now been approved and that we can now accelerate pursuit of our dream of building what we believe will be one of the finest state-of-the-art cGMP standard pharmaceutical facilities in Nigeria. Even more importantly, the Ex-Im guaranteed loan will help insure that we can produce commercial scale quantities of NICOSAN(TM) to meet the needs of the millions of people afflicted with this terrible disease. We are very grateful to Ex-Im Bank, UPS Business Credit, Access Bank and Diamond Bank, as well as our financial consultants, Financialbridge, Inc., for their support for this important project and for helping us make the dream a reality."
About Sickle Cell Disease
Sickle Cell Disease (SCD) is an inherited blood disorder caused by an abnormality in the hemoglobin molecule. Patients with the disease often produce stiff, abnormally shaped red blood cells that often do not flow freely through the blood vessels. This can create clogs in the vessels, which in turn can cut off the flow of normal hemoglobin and oxygen to parts of the body, and can cause severe painful attacks or "crises", damage to various organs and shortened life spans. People with SCD often suffer unpredictable painful crises several times a year lasting from a few hours to a week or more. In the US, there are approximately 80,000 patients with SCD. In Nigeria, that number is believed to be approximately 4 million, with an estimated 10 - 12 million sufferers throughout the African continent. Worldwide, at least 16 million individuals are believed to be afflicted with SCD.
About Xechem
Xechem International is a development stage biopharmaceutical company working on Sickle Cell Disease (SCD), antimalarials, and antiviral (including AIDS), anticancer, antifungal and antibacterial products from natural sources, including microbial and marine organisms. Its primary focus is on the development of phyto-pharmaceuticals (Natural Herbal Drugs) and other proprietary technologies, including those used in the treatment of orphan diseases. Xechem's mission is to bring relief to the millions of people who suffer from these diseases. Its recent focus and resources have been directed primarily toward the development and launch of NICOSAN(TM) (named HEMOXIN(TM) in the US and Europe) for the prophylactic management of Sickle Cell Disease (SCD). With the recent Nigerian regulatory approval of NICOSAN(TM), Xechem is now scaling-up the commercialization of the drug in Nigeria and making preparations for the pursuit of US FDA and European regulatory approval. In addition to NICOSAN(TM), Xechem is also working on another sickle cell compound, 5-HMF, which it has licensed from Virginia Commonwealth University.
U.S. Ex-Im Bank has Approved Comprehensive Guarantee to Support $9.38 Million Loan from UPS Capital to Xechem Pharmaceuticals Nigeria
October 18, 2006 12:46:09 (ET)
NEW BRUNSWICK, N.J., Oct 18, 2006 (BUSINESS WIRE) -- Xechem International, Inc. (XKEM, Trade) announced today that the United States Export Import (Ex-Im) Bank, the official credit export agency of the United States, has approved a Comprehensive Credit Guarantee to support a $9.38 million loan from UPS Capital Business Credit to Xechem Pharmaceuticals Nigeria, Ltd. (Xechem Nigeria). Two Nigerian banks, Access Bank Plc. and Diamond Bank, Plc., are to provide the required Nigerian local bank guarantees in favor of Ex-Im Bank.
Funds Earmarked for Establishment of State-of-the-Art Pharmaceutical Facility in Sheda Science Village, Sheda, FCT, Abuja, Nigeria
The funds to be provided by UPS Capital under the Ex-Im guaranteed loan will be used to purchase the U.S. manufactured plant equipment and machinery needed by Xechem Nigeria to establish a state-of-the-art pharmaceutical facility. The first phase of construction of the new facility began in July of this year. The total cost of the project is estimated at $12.45 million, of which $9.38 million will come from the U.S. loan. The expanded pharmaceutical facility, once completed, will enable Xechem Nigeria to produce commercial scale quantities of NICOSAN(TM), Xechem's breakthrough medicine for the prophylactic management of Sickle Cell Disease (SCD).
Xechem Nigeria received regulatory approval for the manufacture, sales and marketing of NICOSAN(TM) from Nigeria's National Agency for Food and Drug Administration and Control (NAFDAC) on July 3rd, 2006, and officially launched the drug just a few days later at a ceremony presided over by His Excellency, General Olusegun Obasanjo, the President of Nigeria. The drug is currently being produced by Xechem Nigeria in limited quantities at its pilot-scale facility in Abuja.
Dr. Ramesh Pandey, Chairman and CEO of the Xechem Companies said, "We are very pleased that this most anticipated guarantee from the U.S. Ex-Im Bank has now been approved and that we can now accelerate pursuit of our dream of building what we believe will be one of the finest state-of-the-art cGMP standard pharmaceutical facilities in Nigeria. Even more importantly, the Ex-Im guaranteed loan will help insure that we can produce commercial scale quantities of NICOSAN(TM) to meet the needs of the millions of people afflicted with this terrible disease. We are very grateful to Ex-Im Bank, UPS Business Credit, Access Bank and Diamond Bank, as well as our financial consultants, Financialbridge, Inc., for their support for this important project and for helping us make the dream a reality."
About Sickle Cell Disease
Sickle Cell Disease (SCD) is an inherited blood disorder caused by an abnormality in the hemoglobin molecule. Patients with the disease often produce stiff, abnormally shaped red blood cells that often do not flow freely through the blood vessels. This can create clogs in the vessels, which in turn can cut off the flow of normal hemoglobin and oxygen to parts of the body, and can cause severe painful attacks or "crises", damage to various organs and shortened life spans. People with SCD often suffer unpredictable painful crises several times a year lasting from a few hours to a week or more. In the US, there are approximately 80,000 patients with SCD. In Nigeria, that number is believed to be approximately 4 million, with an estimated 10 - 12 million sufferers throughout the African continent. Worldwide, at least 16 million individuals are believed to be afflicted with SCD.
About Xechem
Xechem International is a development stage biopharmaceutical company working on Sickle Cell Disease (SCD), antimalarials, and antiviral (including AIDS), anticancer, antifungal and antibacterial products from natural sources, including microbial and marine organisms. Its primary focus is on the development of phyto-pharmaceuticals (Natural Herbal Drugs) and other proprietary technologies, including those used in the treatment of orphan diseases. Xechem's mission is to bring relief to the millions of people who suffer from these diseases. Its recent focus and resources have been directed primarily toward the development and launch of NICOSAN(TM) (named HEMOXIN(TM) in the US and Europe) for the prophylactic management of Sickle Cell Disease (SCD). With the recent Nigerian regulatory approval of NICOSAN(TM), Xechem is now scaling-up the commercialization of the drug in Nigeria and making preparations for the pursuit of US FDA and European regulatory approval. In addition to NICOSAN(TM), Xechem is also working on another sickle cell compound, 5-HMF, which it has licensed from Virginia Commonwealth University.
U.S. Ex-Im Bank has Approved Comprehensive Guarantee to Support $9.38 Million Loan from UPS Capital to Xechem Pharmaceuticals Nigeria
October 18, 2006 12:46:09 (ET)
NEW BRUNSWICK, N.J., Oct 18, 2006 (BUSINESS WIRE) -- Xechem International, Inc. (XKEM, Trade) announced today that the United States Export Import (Ex-Im) Bank, the official credit export agency of the United States, has approved a Comprehensive Credit Guarantee to support a $9.38 million loan from UPS Capital Business Credit to Xechem Pharmaceuticals Nigeria, Ltd. (Xechem Nigeria). Two Nigerian banks, Access Bank Plc. and Diamond Bank, Plc., are to provide the required Nigerian local bank guarantees in favor of Ex-Im Bank.
Funds Earmarked for Establishment of State-of-the-Art Pharmaceutical Facility in Sheda Science Village, Sheda, FCT, Abuja, Nigeria
The funds to be provided by UPS Capital under the Ex-Im guaranteed loan will be used to purchase the U.S. manufactured plant equipment and machinery needed by Xechem Nigeria to establish a state-of-the-art pharmaceutical facility. The first phase of construction of the new facility began in July of this year. The total cost of the project is estimated at $12.45 million, of which $9.38 million will come from the U.S. loan. The expanded pharmaceutical facility, once completed, will enable Xechem Nigeria to produce commercial scale quantities of NICOSAN(TM), Xechem's breakthrough medicine for the prophylactic management of Sickle Cell Disease (SCD).
Xechem Nigeria received regulatory approval for the manufacture, sales and marketing of NICOSAN(TM) from Nigeria's National Agency for Food and Drug Administration and Control (NAFDAC) on July 3rd, 2006, and officially launched the drug just a few days later at a ceremony presided over by His Excellency, General Olusegun Obasanjo, the President of Nigeria. The drug is currently being produced by Xechem Nigeria in limited quantities at its pilot-scale facility in Abuja.
Dr. Ramesh Pandey, Chairman and CEO of the Xechem Companies said, "We are very pleased that this most anticipated guarantee from the U.S. Ex-Im Bank has now been approved and that we can now accelerate pursuit of our dream of building what we believe will be one of the finest state-of-the-art cGMP standard pharmaceutical facilities in Nigeria. Even more importantly, the Ex-Im guaranteed loan will help insure that we can produce commercial scale quantities of NICOSAN(TM) to meet the needs of the millions of people afflicted with this terrible disease. We are very grateful to Ex-Im Bank, UPS Business Credit, Access Bank and Diamond Bank, as well as our financial consultants, Financialbridge, Inc., for their support for this important project and for helping us make the dream a reality."
About Sickle Cell Disease
Sickle Cell Disease (SCD) is an inherited blood disorder caused by an abnormality in the hemoglobin molecule. Patients with the disease often produce stiff, abnormally shaped red blood cells that often do not flow freely through the blood vessels. This can create clogs in the vessels, which in turn can cut off the flow of normal hemoglobin and oxygen to parts of the body, and can cause severe painful attacks or "crises", damage to various organs and shortened life spans. People with SCD often suffer unpredictable painful crises several times a year lasting from a few hours to a week or more. In the US, there are approximately 80,000 patients with SCD. In Nigeria, that number is believed to be approximately 4 million, with an estimated 10 - 12 million sufferers throughout the African continent. Worldwide, at least 16 million individuals are believed to be afflicted with SCD.
About Xechem
Xechem International is a development stage biopharmaceutical company working on Sickle Cell Disease (SCD), antimalarials, and antiviral (including AIDS), anticancer, antifungal and antibacterial products from natural sources, including microbial and marine organisms. Its primary focus is on the development of phyto-pharmaceuticals (Natural Herbal Drugs) and other proprietary technologies, including those used in the treatment of orphan diseases. Xechem's mission is to bring relief to the millions of people who suffer from these diseases. Its recent focus and resources have been directed primarily toward the development and launch of NICOSAN(TM) (named HEMOXIN(TM) in the US and Europe) for the prophylactic management of Sickle Cell Disease (SCD). With the recent Nigerian regulatory approval of NICOSAN(TM), Xechem is now scaling-up the commercialization of the drug in Nigeria and making preparations for the pursuit of US FDA and European regulatory approval. In addition to NICOSAN(TM), Xechem is also working on another sickle cell compound, 5-HMF, which it has licensed from Virginia Commonwealth University.
SWKJ bro, did it change to SBDN?
oops, just found it, yes still in it,
08/03/2006 SWKJ to SBDN
My big stock is XKEM, all ready made a ton and still accumulating. Never had SBDN unless it is a changed ticker symbol.
Still here too with my shares also, just waiting for Mario to get out of the barber shop office. ;)
E*Trade shows 5 Institutional Holdings, numbers are going up.
How many penny stocks get grants and loans, THIS IS THE REAL DEAL HERE.
To all the great minds of XKEM, can anyone answer this question or are YOU-ALL just flippers?
Will XKEM need loan approval if they get 5 billion share approval as stated in their voting proxy? Just curious.
Will XKEM need loan approval if they get 5 billion share approval? Just curious.
test
Ask Mario, "hows the barber shop?"
On vacation, see you in six to nine months, let the MM's play.
Ask Mario, Hows the barber shop.
These are XKEM sells, could be who Chassman is using.
ALPHA CAPITAL AKTIEN... 07/12/2006 12,850,000
MONTAUK FINANCIAL GR...
ALPHA CAPITAL AKTIEN... 07/12/2006 1,093,470
MONTAUK FINANCIAL GR..
Almost 14 mil .
All we need is SATAN from RB and we will be over .10 today.
"non-toxic 73% effective treatment"
AND THE WORLD WILL KNOW THIS ! MAN
Actually, E*Trade is showing 5 institutions holding now, use to be just 3.
Lets hope bashing SATAN from RB shows up so we can get back to .11.
FWIW, so you got a 5k fill:
5000 X .029 = $145.00, how much commission do you pay?
Use your AON option to get full tade of 125k.
There is a reason for no volume, I am not the teacher gentleman.
GET READY
BOOOOOOOOOOOOOOOOOOOOOOOOOOM
You will have to start paying to get this XKEM stock.
Dude, just GOOGLE "level II" quotes.
Yes this is sometimes a "FRIDAY'S" episode.
Back to .04 today.
i AGREE